Chapters

Transcript

Video

Given the new AHA Guidelines and the anticipation of new ESC Guidelines in 2019, what is your view about LDL-C level target thresholds vs. degree of LDL-C reduction? What level do you consider optimal in high-risk patients with progressive ASCVD?

Given the new AHA Guidelines and the anticipation of new ESC Guidelines in 2019, what is your view about LDL-C level target thresholds vs. degree of LDL-C reduction? What level do you consider optimal in high-risk patients with progressive ASCVD?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Dan Atar, MD

Dan Atar, MD

Head of Research Oslo University Hospital Ulleval Professors of Cardiology University of Oslo  Oslo, Norway Visiting Associate Professorship  Johns Hopkins University Baltimore, Maryland